NEW HAVEN, Conn., Aug. 1, 2023 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for difficult to treat patients with chronic cough in idiopathic pulmonary fibrosis (IPF), other chronic cough indications, and prurigo nodularis, today announced senior management will attend and participate in the following events in August.
Read more at prnewswire.comTrevi Therapeutics to Participate in Upcoming August Events
PR Newswire - Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here